Domínguez FND, Alban FPE, Carvajal SGE, Simbaña PFM

Language: Spanish
References: 42
Page:
PDF size: 476.36 Kb.

ABSTRACT

Introduction: Numerous types of arthritis have been investigated and described in order to classify them into non-inflammatory arthritis (osteoarthritis) and inflammatory arthritis caused by deposition crystals (pseudogout, basic calcium phosphate disease, gout), by bacteria and viral infections (Staphylococcus aureus, Neisseria gonorrohae, complications of Lyme disease, Parvovirus, Enterovirus) or autoimmune processes.
Objective: research is to present aspects related to the management of Digital Ulcers (DU) in scleroderma based on the experience of different authors, establishing a basis on which future research studies can be designed and improve the patient's quality of life.
Method: A bibliographic search related to the keywords rheumatoid arthritis and other arthritis variables was carried out, recovering 76 documents that included them, of which we used 42 that were useful for the objective that we proposed, exposing the most prominent data in the investigation.
Conclusions: The first step for an effective management of the disease is an early and correct diagnosis, related to the fact that several signs and symptoms are also associated with other diseases, disease prevention strategies as well as prevention programs should be included for this objective. detection of people at risk of developing them, as in the case of rheumatoid arthritis, monographs of the disease provided to the population can significantly improve epidemiological parameters.

REFERENCES

1. Kurowska W, Kuca-Warnawin EH, Radzikowska A, Maslinski W. The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. Cent J Immunol. 2017;42:390-8.

2. Theis KA, Steinweg A, Helmick CG, Courtney-Long E, Bolen JA, Lee R. Which one? What kind? How many? Types, causes, and prevalence of disability among U.S. adults. Disabil. Health J. 2019;12:411-21.

3. Cooper NJ. Economic burden of rheumatoid arthritis: A systematic review. Rheumatology. 2000;39:28-33.

4. Singh A, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1-26.

5. Radu AF, Bungau SG. Management of Rheumatoid Arthritis: An Overview. Cells. 2021;10(11):2857. DOI: https://doi.org/10.3390/cells101128575.

6. Silman AJ, Hochberg M. Descriptive epidemiology of rheumatoid arthritis. In Hetherington P, Ingram J, Forgione L, editors. Rheumatoid Arthritis. Philadelphia: Elsevier; 2009. p. 15-22.

7. Silva L, Macía C, Seoane D, Cortés R, Romero A, Quevedo V, et al. Prevalencia de artritis reumatoide en España. Sci Rep. 2020;10:1-9.

8. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023-38.

9. Myasoedova E, Davis J, Matteson EL, Crowson CS. Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985-2014. Ann Rheum Dis. 2020;79:440-4.

10. Taylor-Gjevre R, Nair B, Jin S, Quail J. Geographic variation in incidence and prevalence rates for rheumatoid arthritis in Saskatchewan, Canada 2001-2014. Can J Public Health. 2018;109:427-35.

11. Parks CG, D' Aloisio AA, De Roo LA, Huiber K, Rider LG, Miller FW, et al. Childhood socioeconomic factors and perinatal characteristics influence development of rheumatoid arthritis in adulthood. Ann Rheum Dis. 2013;72:350-6.

12. Almoallim H, Al Saleh J, Badsha H, Ahmed HM, Habjoka S, Menassa S, et al. A Review of the prevalence and unmet needs in the management of rheumatoid arthritis in Africa and the Middle East. Rheumatol Ther. 2020;8:1-16.

13. Macgregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 2000;43:30-7.

14. Sigurdsson S, Padyukov L, Kurreeman FAS, Liljedahl U, Wiman AC, Alfredsson L, et al. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum. 2007;56:2202-10.

15. Vessey MP, Villard L, Yeates D. Oral contraceptives, cigarette smoking and other factors in relation to arthritis. Contraception. 1987;35:457-64.

16. Ishikawa Y, Terao C. The impact of cigarette smoking on risk of rheumatoid arthritis: A narrative review. Cells. 2020;9:475.

17. Hedström AK, Klareskog L, Alfredsson L. Exposure to passive smoking and rheumatoid arthritis risk: Results from the Swedish EIRA study. Ann Rheum Dis. 2018;77:970-2.

18. Alaya Z, Braham M, Aissa S, Kalboussi H, Bouajina E. A case of Caplan syndrome in a recently diagnosed patient with silicosis: Radiol Case Rep. 2018;13:663-6.

19. Mehta B, Pedro S, Ozen G, Kalil A, Wolfe F, Mikuls T, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: A US national cohort study. RMD Open. 2019;5:e000935.

20. Perricone C, Ceccarelli F, Saccucci M, di Carlo G, Bogdanos DP, Lucchetti R, et al. Porphyromonas gingivalis and rheumatoid arthritis. Curr Opin Rheumatol. 2019;31:517-24.

21. Curran AM, Naik P, Giles JT, Darrah E. PAD enzymes in rheumatoid arthritis: Pathogenic effectors and autoimmune targets. Nat Rev Rheumatol. 2020;16:301-15.

22. Van Drongelen V, Holoshitz J. HLA-disease associations in rheumatoid arthritis. Rheum Dis Clin North Am. 2017;43:363-76.

23. Stavnezer J, Guikema JEJ, Schrader CE. Mechanism and regulation of class switch recombination. Annu Rev Immunol. 2008;26:261-92.

24. Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: Clinical applications. Dis Markers. 2013;35:727-34.

25. Yu HC, Lu MC. The roles of anti-citrullinated protein antibodies in the immunopathogenesis of rheumatoid arthritis. Tzu-Chi Med J. 2019;31:5-10.

26. Wells PM, Williams FMK, Matey-Hernandez ML, Menni C, Steves CJ. RA and the microbiome: Do host genetic factors provide the link? J Autoimmun. 2019;99:104-15.

27. Radner H, Neogi T, Smolen JS, Aletaha D. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: A systematic literature review. Ann Rheum Dis. 2014;73:114-23.

28. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-81.

29. Jeffery RC. Clinical features of rheumatoid arthritis. Medicine. 2014;42:231-6.

30. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: A review. JAMA. 2018;320:1360-72.

31. Wasserman A. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2011;84:1245-52.

32. Rasmussen A, Radfar L, Lewis D, Grundahl K, Stone DU, Kaufman A, et al. Previous diagnosis of Sjögren's Syndrome as rheumatoid arthritis or systemic lupus erythematosus. Rheumatology. 2016;55:1195-201.

33. Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. Infect Dis Clin N Am. 2015;29:269-80.

34. Banal F, Dougados M, Combescure C, Gossec L. Sensitivity and specificity of the American College of Rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration: A systematic literature review and meta-analysis. Ann Rheum Dis. 2009;68:1184-91.

35. Maksymowych WP, Naides SJ, Bykerk V, Siminovitch KA, van Schaardenburg D. Serum 14-3-3? is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol. 2014;41:2104-13.

36. Zeng T, Tan L. 14-3-3 ? protein: A promising biomarker for rheumatoid arthritis. Biomark Med. 2018;12:917-25.

37. Mohamed SR, Neseem NO, Metwally SS, El-Kady BA. Diagnostic value and clinical significance of anti-carbamylated protein (anti-CarP) antibodies in Egyptian patients with rheumatoid arthritis. Egypt Rheumatol. 2020;42:1-4.

38. Spierings J, van Eden W. Heat shock proteins and their immunomodulatory role in inflammatory arthritis. Rheumatology. 2017;56:198-208.

39. Mun S, Lee J, Park M, Shin J, Lim MK, Kang HG. Serum biomarker panel for the diagnosis of rheumatoid arthritis. Arthritis Res Ther. 2021;23:1-10.

40. Väänänen T, Vuolteenaho K, Kautiainen H, Nieminen R, Möttönen T, Hannonen P, et al. Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial. PLoS ONE. 2017;12:e0183294.

41. Albrecht K, Zink A. Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: A review of data from randomized clinical trials and cohort studies. Arthritis Res Ther. 2017;19:1-8.

42. Marotta A, Maksymowych WP. SAT0070 levels of 14-3-3eta predict good EULAR response to anti-TNF treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2014;73:615-6.